Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 23685934.
- Also identified by DOI 10.1212/WNL.0b013e318297eea6 and PMC identifier 3770207.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Secondary malignancies due to alkylating agents or topoisomerase II inhibitors are a concern in patients treated for primary brain tumors of the nervous system. Myelosuppression is the dose-limiting toxic effect of the alkylating agent temozolomide; reversible hematologic toxicity consisting mainly of thrombocytopenia is reported to occur in 7% of patients treated with concomitant radiotherapy and temozolomide and 14% with adjuvant temozolomide.<sup>1</sup> However, the incidence of secondary malignancies and nonreversible hematologic disorders, such as myelodysplastic syndrome, are a rare complication of temozolomide.<sup>2</sup>
Medical subject headings
- Antineoplastic Agents, Alkylating
- Brain Neoplasms
- Dacarbazine
- Glioblastoma
- Lymphoma